GluA2-Selective Aptamer Inhibitors for AMPA Receptors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current AMPA glutamate receptor inhibitors are limited by cross-activity with other receptors, poor water solubility, and inability to selectively target a single subunit, which hampers their effectiveness in treating neurological disorders like ALS and Alzheimer's disease.
Innovation Solution
Development of nucleic acid ligands, specifically aptamers, that selectively inhibit the GluA2 AMPA receptor subunit with high affinity and specificity, targeting the closed-channel conformation without affecting other subunits or receptors, and are water-soluble.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional AMPA glutamate receptor inhibitors are used, then receptor activity is inhibited, but cross-activity with other receptors occurs and subunit selectivity is lost
Solution Approach 1:
The patent applies segmentation by designing aptamers that specifically target individual AMPA receptor subunits (GluA1, GluA2, GluA3, or GluA4) rather than inhibiting all AMPA receptors non-selectively. Each aptamer is engineered to recognize and bind to a specific subunit, dividing the broad inhibitory action into subunit-specific actions, thereby achieving both effectiveness and selectivity simultaneously
Solution Approach 2:
The patent implements local quality by creating aptamers with distinct binding specificities for different subunits. Each aptamer possesses unique structural and sequence characteristics that enable it to interact preferentially with its target subunit's specific binding site, while showing minimal or no activity toward other subunits or receptor types, thus achieving subunit-selective inhibition
2Reliability
If conventional AMPA glutamate receptor inhibitors are used, then receptor activity is inhibited, but water solubility is poor
Solution Approach 1:
The patent applies parameter changes by utilizing the inherent water solubility characteristics of nucleic acid molecules. The aptamers are designed with nucleotide sequences that can be formulated in aqueous solutions, and their solubility can be further optimized through chemical modifications such as adding hydrophilic groups or using specific nucleotide compositions, thereby achieving both effective inhibition and improved water solubility
3Adaptability or versatility
If conventional AMPA glutamate receptor inhibitors are used, then general AMPA receptor activity is reduced, but ability to selectively target single subunit is lost
Solution Approach 1:
The patent enables precise subunit targeting by segmenting the inhibitory action across different aptamers, each dedicated to a specific AMPA receptor subunit. This segmentation allows researchers and clinicians to select and administer the appropriate aptamer based on the specific subunit involved in the neurological disorder, achieving both high specificity and therapeutic versatility
Solution Approach 2:
The patent uses aptamers as intermediary molecules that provide high specificity in binding to target subunits. These nucleic acid-based intermediaries serve as precise mediators between the therapeutic agent and the specific AMPA receptor subunit, enabling selective modulation of subunit activity without affecting other subunits or receptor types
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The aptamers provide a potent and selective means to inhibit AMPA-type glutamate ion channels, offering potential therapeutic benefits for neurological disorders by modulating receptor activity with high specificity and solubility, effectively addressing the limitations of existing inhibitors.
Implementation Method 1
aptamers that selectively bind to a single subunit of the AMPA glutamate receptor
Data Source
AI summary
Inhibitors of AMPA-type glutamate ion channels are useful as biochemical probes for structure-function studies and as drug candidates for a number of neurological disorders and diseases. Disclosed herein is the identification of an RNA inhibitor or aptamer by an in vitro evolution approach and characterization of its mechanism of inhibition on the sites of interaction by equilibrium binding and on the receptor channel-opening rate by a laser-pulse photolysis technique. The aptamer of the invention is a noncompetitive inhibitor of AMPA-type glutamate ion channels, one that selectively inhibits the GluA2Qflip AMPA receptor subunit without any effect on other AMPA receptor subunits or on kainate or NMDA receptors. Furthermore, the aptamer preferentially inhibits the closed-channel state of GluA2Qflip with a KI=1.5 μM or by ˜15-fold over the open-channel state. The potency and selectivity of this aptamer rival those of small molecule inhibitors. Together, these properties make the aptamers of the present invention promising water-soluble, highly potent, GluA2 subunit-selective drugs.